A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2004
11/25/2004	US20040235740 Administered as antitumor, antimetastasis, anticarcinogenic and/or wound healing agent; tissue regeneration
11/25/2004	US20040235738 Novel antimicrobial peptide isolated from penaeus monodon
11/25/2004	US20040235728 Compositions and methods for treating osteoporosis
11/25/2004	US20040235722 Assay that makes use of the interaction of early pregnancy factor (EPF) or an EPF-related peptide with a human dorsal root receptor (hDRR) or hDRR related receptor; also useful to determine whether the test compound is an agonist or antagonist of hDRRs
11/25/2004	US20040235720 May also be used in combination with an interferon for treatment and/or prevention of diseases such as traumatic nerve injury, stroke, demyelinating diseases of the CNS or PNS, neuropathies and neurodegenerative diseases
11/25/2004	US20040235156 Therapeutic mixture comprising interferons and chimeric immunoglobulins for use in activation of immune response and treatment, diagnosis and prevention of cancer; immunotherapy; tissue targeted therapy
11/25/2004	US20040235129 KDEL receptor inhibitors
11/25/2004	US20040235082 Fat regulation
11/25/2004	US20040235074 Methods for the treatment or prevention of immune disorders using anti-CD40 antibodies
11/25/2004	US20040235018 Nucleotide sequences coding zinc finger protein for use in identifying modulators of cell proliferation disorders; antitumor agents
11/25/2004	US20040235006 Chemical compounds
11/25/2004	US20040234999 Biopolymer mixtures for use in the inhibition of gene expression; RNA interference and gene therapy
11/25/2004	US20040234993 Comprises nucleotide sequences coding membrane protein for use in identifying modulators for prevention and treatment of asthma, chronic obstructive pulmonary disease (COPD) and arthritis
11/25/2004	US20040234969 Using cytochrome p450 gene expression as diagnostic indicator of steroid responsiveness; identifying modulators for treatment and prevention of skin and allergic disorders
11/25/2004	US20040234634 Pharmaceutical compositions having appetite suppressant activity
11/25/2004	US20040234626 Food supplement for increasing lean mass and strength
11/25/2004	US20040234624 Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
11/25/2004	US20040234622 Sulfonamide derivatives
11/25/2004	US20040234621 Mixture of catalytic metal compound, coenzyme, reducing agents or oxidizer and adjuvant; applying as aerosol, or film to medical equipment, filters, air conditioner
11/25/2004	US20040234619 Administering low dosage of anti-pressor agent; sexual disorders
11/25/2004	US20040234611 Active material embedded into biocompatible polymer or lipid
11/25/2004	US20040234594 Inhibiting gastric acid secretory; antiulcer agent; oral dosage form
11/25/2004	US20040234575 Medical products comprising a haemocompatible coating, production and use thereof
11/25/2004	US20040234571 Injecting fluid; applying electric current; tissue engineering; drug delivery; bone reinforcement
11/25/2004	US20040234557 Method for producing a bovine teat dip
11/25/2004	US20040234545 Aids and leukemia therapy; enhancing immunology response; promote secretion of peptide such as defensin
11/25/2004	US20040234544 Formulation containing (lyso-)phosphatidylserine for the prevention and treatment of stress states in warm blooded animals
11/25/2004	US20040234526 Use of a compound antagonist of esm-1 protein for producing a medicine for treating cancer
11/25/2004	US20040234523 Antiischemic agents; synergistic mixture of interleukin inhibitor and tumor necrosis factor antagonist
11/25/2004	US20040234520 Uses for Eph receptor antagonists and agonists
11/25/2004	US20040234513 Composition and method for reducing blood glucose
11/25/2004	US20040234512 Method for treating thrombopoiesis and anemia; cytosine phosphate diester guanine; controlling remodeling of immunology system
11/25/2004	US20040234502 Method for treatment of vascular regeneration
11/25/2004	US20040234457 in situ administering into respiratory system a mixture of organic acid and metal compound
11/25/2004	US20040232205 Lantibiotic
11/25/2004	US20040232089 Adding menadione nicotinamide bisulphite, menadione dimethylpyrimidinole bisulphite, menadione nicotinic acid bisulphite, menadione adenine bisulphite, menadione triptophane bisulphite, menadione histidine bisulphite, menadione para-aminobenzoic acid bisulphite to the water for elimination or prevention
11/25/2004	US20040231666 Adsorbents and uses thereof
11/25/2004	CA2617420A1 Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
11/25/2004	CA2526025A1 Preventive and/or remedy for diseases accompanied by tissue destruction
11/25/2004	CA2525929A1 Methods of modulating metastasis and skeletal related events resulting from metastases
11/25/2004	CA2525665A1 Pharmaceutical composition comprising valsartan
11/25/2004	CA2525526A1 Combination of the analeptic modafinil and an antidepressant for the treatment of depression
11/25/2004	CA2525366A1 Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
11/25/2004	CA2523940A1 Method and kit for regulation of microvascular tone
11/25/2004	CA2522765A1 Dietary supplement and method for the treatment and prevention of digestive tract ulcers in equines and other animals
11/25/2004	CA2522404A1 One or several enzyme-containing compounds, dietetic food products and drugs produced from said compounds and the use therefor for medical purposes
11/24/2004	EP1479768A1 Novel screening method
11/24/2004	EP1479398A1 AGENT CONTROLLING THE APOPTOSIS INDUCTION BY p73
11/24/2004	EP1479396A1 Drugs ameliorating circadian rhythum disorder
11/24/2004	EP1479395A1 Modified factor VII
11/24/2004	EP1479394A1 The use of epidermal growth factor (EGF) for increasing weight gain in an animal
11/24/2004	EP1479386A1 Use of isoquinoline-derivatives for treating and preventing pigmentary disorders
11/24/2004	EP1479385A1 Use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
11/24/2004	EP1479373A1 Hair growth compositions and uses
11/24/2004	EP1479295A1 Use of naphtoquinone compounds for the preparation of biocidal compositions
11/24/2004	EP1478773A2 Methods for assessing and treating leukemia
11/24/2004	EP1478770A2 Screening method for orthopoxvirus antivirals
11/24/2004	EP1478766A2 Methods for determining the influence of protein binding on antiretroviral activity
11/24/2004	EP1478762A2 Nucleic acid-associated proteins
11/24/2004	EP1478745A2 Kinases and phosphatases
11/24/2004	EP1478660A2 KAPPA−PVIIA−RELATED CONOTOXINS AS ORGAN PROTECTANTS
11/24/2004	EP1478648A2 Phosphorus-containing compounds uses thereof
11/24/2004	EP1478620A1 Phenethanolamine derivatives for treatment of respiratory diseases
11/24/2004	EP1478400A1 Therapy for the treatment of migraine comprising anticonvulsant derivatives and antimigraine agents
11/24/2004	EP1478399A1 Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
11/24/2004	EP1478398A1 New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors
11/24/2004	EP1478397A1 Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
11/24/2004	EP1478396A1 Process for the preparation of a nutrient formulation
11/24/2004	EP1478384A2 Method for increasing the survival of dopamine secreting cells
11/24/2004	EP1478380A2 Use of tyrosine kinase inhibitors for treating cns disorders
11/24/2004	EP1478375A1 Compositions for the treatment of pilosebaceous gland inflammations comprising aluminium fluoride
11/24/2004	EP1478374A1 Formulations comprising psychotropic drugs and selenium
11/24/2004	EP1478372A1 Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound
11/24/2004	EP1478371A2 Methods and products for enhancing immune responses using imidazoquinoline compounds
11/24/2004	EP1478368A1 Use of benzothiazepines having activity as inhibitors of ileal bile acid transport for reducing cholesterololemia
11/24/2004	EP1478366A1 Pharmaceutical combinations of cox-2 inhibitors and opiates
11/24/2004	EP1478362A1 A combination treatment for acute myocardial infarction
11/24/2004	EP1478357A2 Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
11/24/2004	EP1478355A2 Antitumor compositions containing taxane derivatives
11/24/2004	EP1478354A2 Use of tgf-beta antagonists to treat or to prevent chronic transplant rejection
11/24/2004	EP1478337A1 System for transvaginal drug delivery
11/24/2004	EP1478327A2 Method of reducing and treating uvb-induced immunosuppression
11/24/2004	EP1478322A2 Beta-2'-OR 3'-HALONUCLEOSIDES
11/24/2004	EP1478276A2 Novel targeted compositions for diagnostic and therapeutic use
11/24/2004	EP1420799A4 Use of atazanavir in hiv therapy
11/24/2004	EP1318976B1 Substituted aminopropoxyaryl derivatives useful as agonists for lxr
11/24/2004	EP1307201B1 Selective pde 2 inhibitors, used as medicaments for improving cognition
11/24/2004	EP1263747B1 1,5-benzothiazepines and their use as hypolipidaemics
11/24/2004	EP1261324B1 Use of tramadol for the preparation of a medicament for the treatment of functional gastrointestinal disorders
11/24/2004	EP1221917B1 Drug delivery device
11/24/2004	EP1214078B1 Formulations for parenteral use of estramustine phosphate and amino acids
11/24/2004	EP1200470B1 Globular assembly of amyloid beta protein and uses thereof
11/24/2004	EP1175214B1 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
11/24/2004	EP1144673A4 Methods of screening protease inhibitors, of inducing mice susceptible to hiv protease inhibitor-induced dyslipidemia, and genes associated therewith
11/24/2004	EP1135519A4 Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases
11/24/2004	EP1109572A4 Neuroprotection
11/24/2004	EP1094711B1 Methods for eradication of nanobacteria
11/24/2004	EP1033985B1 Stable ascorbic acid preparation for topical use
11/24/2004	EP1014886B1 Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
11/24/2004	EP0946185B1 PHARMACEUTICAL COMPOSITION COMPRISING A COMPOUND HAVING ANTI-Xa ACTIVITY AND A PLATELET AGGREGATION ANTAGONIST COMPOUND

1 ... 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 ... 1151